ArticleMolecular biology reports2026
Genetic variations of STAT3 gene and their role in hodgkin lymphoma incidence.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrevious research has associated STAT3 with cancer development and progression, highlighting its role in supporting precise immune surveillances and regulating pathogenic inflammations. STAT3 is emerging as a crucial transcription factor in the battle of the host against tumors. However, the specific effects of this gene on Hodgkin lymphoma (HL) remain unexplored.
objectivesThis study emphasizes the role of STAT3 gene expression and polymorphisms, particularly SNPs rs744166 A/G and rs72823022 T/C, with an increased incidence in Iraqi patients diagnosed with this type of lymphoma. MATERIALS AND
methodsA study at the Baghdad Cancer/Health Directorate/Baghdad/ Iraq involved 100 participants (50 HL and 50 controls) Hematological parameters, along with serum levels of urea and creatinine, were measured in both groups. Quantitative reverse transcription PCR (RT-qPCR) was used to assess STAT3 gene expression. Molecular analyses were performed using polymerase chain reaction (PCR).
resultsThe results showed that The mean fold change in STAT3 gene expression (2-ΔΔCt) was higher in HL patients (4.716) than in the control group. According to the studied SNPs, some genotypes and mutant alleles appeared to have significant protective effects, whereas others appeared to be risk factors that play a significant role in increasing HL incidence.
conclusionsThe results of our investigation revealed that genetic variations in STAT3 may be associated with HL incidence, highlighting it as a possible target for diagnosis and therapeutic intervention.
Indexed as
Identifiers
41718849What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.